Biotech's movers for the week of August 31th and two catalysts to watch for the week ahead
Akeso and Summit scored a win in China for the PD1 x VEGF while Ultragenyx sadly did not succeed in Angelman syndrome. Tyra Biosciences announced a bladder cancer readout will be coming next week.









.png)